{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:00:22Z","timestamp":1790791222714,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["R-1705-27628"],"award-info":[{"award-number":["R-1705-27628"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["B7493-W"],"award-info":[{"award-number":["B7493-W"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 RX002682-01"],"award-info":[{"award-number":["I01 RX002682-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"Multiple Sclerosis Society of Canada","doi-asserted-by":"publisher","award":["1073-A-4"],"award-info":[{"award-number":["1073-A-4"]}],"id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002369"],"award-info":[{"award-number":["UL1TR002369"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.kint.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T17:32:04Z","timestamp":1634578324000},"page":"1208-1213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)\u2013associated membranous nephropathy"],"prefix":"10.1016","volume":"100","author":[{"given":"Rebecca I.","family":"Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole K.","family":"Andeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela C.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary H.","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin","family":"Waslo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali S.","family":"Avasare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.10.010_bib1","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1111\/ajt.16610","article-title":"Posttransplant nephrotic syndrome resulting from NELL1-positive membranous nephropathy","volume":"21","author":"Munch","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2021.10.010_bib2","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1212\/NXI.0000000000000374","article-title":"Lipoic acid in secondary progressive MS: a randomized controlled pilot trial","volume":"4","author":"Spain","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.kint.2021.10.010_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archinte.1980.00040020954016","article-title":"Methyldopa: mechanisms and treatment 25 years later","volume":"140","author":"Frohlich","year":"1980","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2021.10.010_bib4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJM197805252982101","article-title":"Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome","volume":"298","author":"Woosley","year":"1978","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.010_bib5","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1681\/ASN.2011060610","article-title":"Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy","volume":"22","author":"Cravedi","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.10.010_bib6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.10.010_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.10.010_bib8","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ndt\/gfv228","article-title":"Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy","volume":"30","author":"Hoxha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.10.010_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.010_bib10","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.010_bib11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.10.010_bib12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.10.010_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.10.010_bib14","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.10.010_bib15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.10.010_bib16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.11860720","article-title":"Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients","volume":"16","author":"Wang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.10.010_bib17","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/ndt\/gfn350","article-title":"Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands","volume":"23","author":"Hofstra","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.10.010_bib18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/antiox9101011","article-title":"Safety evaluation of alpha-lipoic acid supplementation: a systematic review and meta-analysis of randomized placebo-controlled clinical studies","volume":"9","author":"Fogacci","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.kint.2021.10.010_bib19","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc11-0503","article-title":"Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial","volume":"34","author":"Ziegler","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2021.10.010_bib20","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.2337\/dc07-0689","article-title":"Alpha-lipoic acid and insulin autoimmune syndrome","volume":"30","author":"Ishida","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2021.10.010_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nut.2018.04.010","article-title":"Potential cause-effect relationship between insulin autoimmune syndrome and alpha lipoic acid: two case reports","volume":"57","author":"Moffa","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.kint.2021.10.010_bib22","doi-asserted-by":"crossref","first-page":"102041","DOI":"10.1016\/j.msard.2020.102041","article-title":"Cross-sectional survey of complementary and alternative medicine used in Oregon and southwest Washington to treat multiple sclerosis: a 17-year update","volume":"41","author":"Silbermann","year":"2020","journal-title":"Mult Scler Relat Disord"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821009467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821009467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:27:35Z","timestamp":1778664455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821009467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0085253821009467"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.10.010","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)\u2013associated membranous nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}